Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430137 | 0.81 | JAK2 (0.77) | JAK2 | |
| SCHEMBL1726771 | 0.78 | SPAST (0.47) | JAK2 | |
| SCHEMBL1723132 | 0.76 | JAK2 (0.37) | JAK2RET | |
| SCHEMBL1722352 | 0.72 | JAK2 (0.58) | JAK2 | |
| SCHEMBL3922274 | 0.72 | RET (0.41) | JAK2RET | |
| SCHEMBL3924185 | 0.71 | JAK2 (0.37) | JAK2RET | |
| SCHEMBL4213948 | 0.71 | JAK2 (0.37) | JAK2RET | |
| SCHEMBL1299269 | 0.71 | AURKA (0.43) | JAK2RET | |
| SCHEMBL1270105 | 0.71 | IGF1R (0.42) | JAK2RET | |
| SCHEMBL25204317 | 0.70 | ACVR1 (0.64) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344504-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8445676-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| EP-2344504-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042684-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, CSNK2A1, CSNK2A2 | JAK2 1/4885RET 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.